hello freinds
this chart we shows that this market will know an uptrend on next days when i recommend buying with a fort probability
if you have any questions you can write it in commentaire below and i will answer them
and please don't forget to support this ideas with your like and comment thank you
cordialy
The PEAD projected a Bearish outlook for $BIIB after a Negative Under reaction following its earnings release placing the stock in drift D with an expected accuracy of 100%.
Looking at the options chain today, i would buy the $255 calls with
2022-9-16 expiration date for about
$3.40 premium.
Looking forward to read your opinion about it.
My recent post was a bearish view for BIIB, it included some Fibonacci Circles and I am questioning my ability to plot these.
So I have posted a much simpler chart that shows a dominant trend line in green that should be maintained
Once the descending channel reaches this level price should move upwards.
Here is the bear view
Remains a very risky trade.
A falling wedge pattern might be developing. The break usually occurs to the upside.
Above 190.00 supports a bullish trend direction. Crossing below this level will negate the positive stance.
Further bullish support for a price action above 197.50.
Consolidation is between 193.75 and 201.25. Crossing above 201.25 might target...
The PEAD projected a Bullish outlook for $BIIB after a Positive Under reaction following its earnings release placing the stock in drift A with an expected accuracy of 87.5%.
Coiling and looks to be painting a 5 wave C here. About to tap 200 MONTH MA and a lifetime .618 retrace to end wave II to start a potentially massive wave III. Will potentially trade all the way down to 140s but am going to start nibbling here for a lifetime HODL.
We're getting close the descending wedge and we're touching multi-year support at around 205. $BIIB has been in a downtrend since June with no signs of life so we could see a bounce or breakdown to lower lows.
The basics:
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. I expect this industry to continue to grow as new advancements are made.
Trade Idea:
Since September of 2013 Biogen...
I think it warrants making a new publication here, $BIIB has flashed a buy signal with tremendously good reward to risk, as it can resume the long term trend that can take it over $1600-2600 over time. Phase 3 clinical trials have gone really well for their Alzheimer's treatment 'Aduhelm', putting it in line with results obtained by $LLY's drug 'Donanemab'. I was...
MID-TERM: Double bottom at an iceline with a breakout of a falling wedge and a double bottom on a wave of classic bullish divergence. (not financial advice)
Reward to risk long term in $BIIB is very attractive here. I've gone long via a calendar spread before the latest FDA approval news, which turned out like a good long position when Biogen's Alzheimer's drug Aduhelm received accelerated approval. Following this, related companies which also have Alzheimer's drugs pending approval (like $LLY) received a dramatic...
